Pharvaris' RAPIDe-3 Phase 3 Trial Of Deucrictibant For The On-demand Treatment Of Hereditary Angioedema Attacks Met The Primary Endpoint Of Median Time To Onset Of Symptom Relief, Achieved In 1.28 Hours, Significantly Faster Than Placebo

2025-12-03 19:56

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001)
All secondary efficacy endpoints met (p<0.0001), including End of Progression™1 (median 17.47 minutes) and complete symptom resolution (median 11.95 hours)
Well-tolerated safety profile of deucrictibant confirmed
Efficacy and safety outcomes consistent across all HAE subtypes represented (HAE type 1, HAE type 2, and HAE with normal C1 inhibitor) and varying attack severities and locations